Clinical trials: Hemodialysis Treatment
Chronic Renal Failure, Chronic Kidney Disease
Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis
The purpose of this study was to evaluate the safety and efficacy of peginesatide in the maintenance treatment of anemia in participants on dialysis.
- Conditions
- Chronic Renal Failure, Chronic Kidney Disease, Anemia
- Trial name
- EMERALD 2 (NCT00597584)
- Testing
- peginesatide, Epoetin alfa or Epoetin beta
- Where
- 84 sites in United States, Bulgaria and 7 more
- Volunteers
- 823 people
- Sponsor
- Affymax
Venous Stenosis, Venous Occlusion
The Merit WRAPSODY™ Endovascular Stent Graft
This is a phase 1 study, designed to evaluate the safety and effectiveness of the WRAPSODY Stent Graft for the treatment of venous outflow circuit obstructions in the veins of the arm or thoracic central veins of subjects who…
- Trial name
- NCT03644017
- Testing
- WRAPSODY Stent Graft Placement
- Where
- 3 sites in Greece, United Kingdom
- Volunteers
- 46 people
- Sponsor
- Merit Medical Systems, Inc.
Anemia
Darbepoetin Alfa Treatment of Anemia in Hemodialysis Subjects
The purpose of this study is to compare once a week and once every other week darbepoetin alfa on the change in hemoglobin levels between the screening/baseline period and the evaluation period (weeks 25-30).
- Trial name
- NCT00119587
- Testing
- darbepoetin alfa
- Sponsor
- Amgen
Fabry Disease
A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease
An Open-label Study to Evaluate the Safety and Pharmacokinetics of Migalastat HCl in Subjects with Fabry Disease and Amenable GLA Variants and Severe Renal Impairment (SRI) or End Stage Renal Disease (ESRD)
- Trial name
- NCT04020055
- Testing
- migalastat HCl 150 mg
- Where
- 12 sites in United States, Australia and 4 more
- Volunteers
- 14 people
- Sponsor
- Amicus Therapeutics
Anemia, Kidney Disease
Efficacy Study: Darbepoetin Alfa for the Treatment of Anemia in Patients With Chronic Kidney Disease
The purpose of this study is to evaluate whether the efficacy of darbepoetin alfa SF is equivalent to that of darbepoetin alfa RB for the treatment of anemia in patients with chronic kidney disease (CKD) receiving hemodialysis.
- Trial name
- NCT00121602
- Testing
- Darbepoetin Alfa
- Volunteers
- 446 people
- Sponsor
- Amgen
Anemia Associated With End Stage Renal Disease
Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants
The purpose of this study is to assess the safety and effectiveness of roxadustat dosing regimens among hemodialysis participants converted from erythropoiesis stimulating agent (ESA) therapy or who are ESA-naïve.
- Trial name
- ASPEN (NCT04484857)
- Testing
- Roxadustat
- Where
- 26 sites in United States
- Volunteers
- 283 people
- Sponsor
- Kyntra Bio
Anemia Associated With End Stage Renal Disease (ESRD)
Study of Roxadustat Conversion in Participants Receiving Stable Erythropoiesis-Stimulating Agent (ESA) or as Initial Anemia Treatment in Chronic Dialysis Participants
The purpose of this study is to assess the safety and effectiveness of Roxadustat dosing regimens among chronic dialysis participants converted from ESA therapy or who are ESA-naïve.
- Trial name
- NCT04410198
- Testing
- Roxadustat
- Where
- 9 sites in United States
- Volunteers
- 203 people
- Sponsor
- Kyntra Bio
Renal Dialysis
Multi-center Study to Investigate the Effects of Citrasate® on Heparin N Requirements During Hemodialysis Treatment
The purpose of this study is to determine whether the use of Citrasate®, citric acid dialysate enables the reduction of the heparin N (anticoagulant) dose in patients undergoing hemodialysis.
- Trial name
- NCT01092455
- Testing
- Heparin N reduction
- Where
- 8 sites in United States
- Volunteers
- 300 people
- Sponsor
- Randolph Quinn
End-Stage Renal Disease Requiring Haemodialysis, Hemodialysis Access Failure (Disorder)
BONE ANCHORED PORT for Hemodialysis Treatment
A Bone Anchored Port System (BAP) will be implanted in the mastoid bone behind the ear, connected with a double lumen central venous catheter inserted in the jugular vein, and will be used in conjunction with an adapter as a…
- Trial name
- BAP (NCT02069860)
- Testing
- Bone Anchored Port System (BAP)
- Where
- Switzerland
- Volunteers
- 6 people
- Sponsor
- Cendres+Métaux
Patient of Anemia in Chronic Renal Failure With Hemodialysis
A Phase 2 Clinical Study of Pegerythropoietin Injection (RD01) for the Treatment of Anemia in Chronic Renal Failure Patients With Hemodialysis
A multicenter randomized, single blind, active comparator controlled phase 2 study which is to evaluate the effectiveness, safety and the PK/PD characteristics of different doses, frequencies and routes of pegerythropoietin…
- Trial name
- NCT04231292
- Testing
- RD01, Recombinant Human Erythropoiesis Injection (CHO cell)
- Where
- China
- Volunteers
- 105 people
- Sponsor
- Shengzhen Sciprogen Bio-pharmaceutical Co. Ltd
Arteriovenous Graft
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Placement of an Arteriovenous Graft to Facilitate Hemodialysis Access
A study to evaluate the efficacy of SRM003 treatment versus participating sites' standard practice treatment in extending the duration of primary patency after arteriovenous graft surgery in subjects with end-stage renal disease.
- Trial name
- NCT01806584
- Testing
- SRM003, Participating Site's standard practice
- Where
- 46 sites in United States
- Volunteers
- 32 people
- Sponsor
- Shire
Hyperparathyroidism
Safety and Efficacy Study of AMG 073 in Hemodialysis Subjects
Subjects on Hemodialysis will be randomized to AMG 073 or placebo. The screening period is a maximum of 30 days followed by a 26-week treatment period.
- Trial name
- NCT00527267
- Testing
- AMG 073
- Volunteers
- 320 people
- Sponsor
- Amgen
Patients on Stable Chronic Maintenance Dialysis Who Are Receiving Hemodialysis Therapy, Pharmacodynamics of ASP7991
Examination of Plasma Concentrations and Safety in Chronic Kidney Disease Patients Undergoing Hemodialysis
This study is to assess the safety, tolerability, plasma concentration and pharmacodynamics of ASP7991 after oral administration to patients with chronic kidney disease undergoing hemodialysis.
- Conditions
- Patients on Stable Chronic Maintenance Dialysis Who Are Receiving Hemodialysis Therapy, Pharmacodynamics of ASP7991, Pharmacokinetics of ASP7991
- Trial name
- NCT01872026
- Testing
- ASP7991
- Where
- Japan
- Volunteers
- 14 people
- Sponsor
- Astellas Pharma Inc
Anemia Associated With Chronic Kidney Disease (CKD)
Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects
This study will be conducted to demonstrate the efficacy and safety of vadadustat administered three times weekly (TIW) compared to a long-acting erythropoiesis-stimulating agent (ESA) (Mircera®) for the maintenance treatment of…
- Trial name
- NCT04707768
- Testing
- Vadadustat, Mircera®
- Where
- 58 sites in United States
- Volunteers
- 456 people
- Sponsor
- Akebia Therapeutics
End Stage Renal Disease
Comparison of the Impact of Dialysis Treatment Type on Patient Survival
As the influence of type of dialysis on survival of end stage renal disease (ESRD) patients remains unanswered, the present study is designed (randomized, prospective, multicenter, interventional) to assess clinical outcomes, and…
- Trial name
- NCT00510549
- Testing
- Modality: Peritoneal Dialysis
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- Baxter Healthcare Corporation
Secondary Hyperparathyroidism
SK-1403 Long-term Treatment Study; Long-term Study in Patients With Secondary Hyperparathyroidism Receiving Hemodialysis
To evaluate the safety and efficacy of treatment with SK-1403 for 52 weeks in patients with secondary hyperparathyroidism on maintenance hemodialysis.
- Trial name
- NCT03626948
- Testing
- SK-1403
- Where
- Japan
- Volunteers
- 157 people
- Sponsor
- Sanwa Kagaku Kenkyusho Co., Ltd.
Anemia
Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Hemodialysis Patients
The study will evaluate the safety and efficacy of a new intravenously administered iron drug to treat anemia in patients on hemodialysis.
- Trial name
- NCT00233597
- Testing
- ferumoxytol or oral iron
- Where
- 50 sites in United States
- Volunteers
- 230 people
- Sponsor
- AMAG Pharmaceuticals, Inc.
Hyperphosphatemia
Dose Finding Study to Treat High Phosphate Levels in the Blood.
Randomized. double blind, placebo controlled, parallel arms dose finding study with a 4 weeks treatment period
- Trial name
- NCT02081534
- Testing
- AZD1722
- Where
- 41 sites in United States, Poland and 2 more
- Volunteers
- 162 people
- Sponsor
- Ardelyx
Anemia
An Observational Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) in Stage V Chronic Kidney Disease Participants on Hemodialysis
This observational study will evaluate the efficacy and use of Methoxy polyethylene glycol-epoetin beta (Mircera) in participants with Stage V chronic kidney disease on hemodialysis receiving an erythropoietin prior to study…
- Trial name
- NCT01940484
- Testing
- Methoxy polyethylene glycol epoetin beta
- Where
- 10 sites in South Africa
- Volunteers
- 98 people
- Sponsor
- Hoffmann-La Roche
Uremic Pruritus
Efficacy and Safety of MT-9938 for Treatment of Uremic Pruritus in Subjects With End-stage Renal Disease Receiving Hemodialysis
This study is being conducted to investigate the efficacy of MT-9938 compared with placebo after 2 weeks, to continue to evaluate efficacy for an additional 6 weeks, and to explore the effect of a reduction in itching intensity…
- Trial name
- NCT01660243
- Testing
- Nalfurafine hydrochloride(MT-9938) 2.5μg, Nalfurafine hydrochloride(MT-9938) 5μg, Nalfurafine hydrochloride(MT-9938) 10μg
- Where
- 4 sites in United States
- Volunteers
- 45 people
- Sponsor
- Toray Industries, Inc